Recent medical research addresses weight-loss drug side effects, emerging therapeutic options, and risks in geriatric prescribing.
Key Points
New data from the ADA Scientific Sessions highlights concerns regarding muscle loss during GLP-1 therapy, prompting expert guidance on patient counseling and risk mitigation.
Clinicians are navigating a surge in patients using unapproved weight-loss drugs like retatrutide, driven by significant social media influence.
Research in obese mouse models indicates that whole-plant cannabis extract may be more effective than isolated THC for improving glucose control.
The potential FDA approval of tavapadon could mark the first introduction of a new dopamine agonist for Parkinson's disease in several decades.
Experts warn that inappropriate prescribing cascades in elderly patients are causing significant harm, as side effects from one medication lead to the unnecessary addition of new prescriptions.
Clinical trial results show that adding atezolizumab to stereotactic body radiation therapy (SBRT) for inoperable NSCLC increases toxicity without improving patient survival.
A narrative review suggests a potential U-shaped relationship between testosterone levels and atrial fibrillation, indicating that both high and low levels may increase cardiovascular risk.
Changing climate patterns are causing an earlier onset of pollen seasons, leading to shifting schedules for allergy symptom management and patient care.